Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration

Development

Latest News


Research into Cold Cancers Heating Up

Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Research into Cold Cancers Heating Up

Proprietary Cell-Line Development for High-Titer AAV Manufacturing

Proprietary cell lines offer opportunities for achieving high AAV titers.

Proprietary Cell-Line Development for High-Titer AAV Manufacturing

Bracing for a Future Wave of Advanced Therapies

In the ATMP space, CGTs are hitting their stride with unprecedented approvals in the past year alone.

Bracing for a Future Wave of Advanced Therapies

Latest Videos


Shorts

Key Biopharma Trends That Emerged in Q3 2025
0:44
Key Biopharma Trends That Emerged in Q3 2025
a year ago
by
Patrick Lavery
Life Science CEOs Making AI a Top Priority: Report
0:31
Life Science CEOs Making AI a Top Priority: Report
a year ago
by
Patrick Lavery

More News

Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com

The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.